Directorio

People in this study will be placed into one of two groups by chance. One group will receive preventive antiviral medicine after their kidney transplant. The other group will receive regular blood testing and treatment only if signs of CMV infection appear. Both approaches are currently recommended for preventing CMV infection after kidney transplant. Participants will have blood tests every three months during the first year and then once a year after that. These tests will check kidney function, blood cell counts, and the body's ability to fight CMV. Researchers want to learn which prevention strategy works best and is safest for kidney transplant recipients.

This study has two parts. The first part includes about eighty people, and the second part includes about two hundred fifty people. Each part of the study lasts about thirty six weeks. The study begins with screening to see if someone can join. After that, people are placed by chance into groups to take either the study medicine or a placebo for about twenty-eight weeks. At the end, there is a follow up period where doctors check safety. Each person will join only one part of the study.

Participants will be placed into one of two groups by chance. One group will receive a new medicine called pasritamig together with a cancer medicine called docetaxel. The other group will receive docetaxel alone. Everyone will continue their usual hormone treatment unless both testicles have been surgically removed. People who receive docetaxel alone will also take a steroid medicine called prednisone. People who receive pasritamig will not take prednisone because it may affect how the study medicine works. Both groups will receive medicines before treatment to help reduce side effects. Researchers will compare the two treatment groups to learn if adding pasritamig can help treat prostate cancer better than standard treatment alone.

We are doing this study to find the most effective, safe dose of an experimental drug called ziftomenib (the study drug). We want to know how well this study drug works in people with AML that have certain mutations in the NPM1 gene and rearrangements involving the KMT2A gene when it is given alone or in combination with other cancer drugs.

We are doing this study to find the most effective, safe dose of an experimental drug called ziftomenib (the study drug) to be used in combination with an established dose of imatinib for people who have advanced gastrointestinal stromal tumors (GIST) and failed treatment with imatinib on its own.

We are doing this study to compare 2 different surgeries for epithelial ovarian cancer. We want to know if an investigational surgical procedure called minimally invasive surgery can offer better results than the standard surgery, which is called laparotomy. We hope to find out if one procedure or the other is preferable when it comes to preventing cancer from returning and giving patients a better quality of life after their surgery.

We are doing this study to find out if a small dose (0.5 mg) of a drug called colchicine (the study drug) is beneficial for people with peripheral artery disease (PAD). We want to know if it has the potential to lower the risk of heart attack, stroke, and corrective leg surgeries for people who have PAD. The study drug is FDA-approved for the treatment of some inflammatory conditions (e.g., gout), but it is not approved for the treatment of PAD.

We are doing this study to support vaccine development by studying blood cells of the immune system.